Showing results (21-30 of 79) with videos related to
Sort By:
Pageof 8
Internal Medicine (Tokyo, Japan)|May 3, 2007
Plasma brain natriuretic peptide during myeloablative stem cell transplantationMasayoshi Masuko, Masahiro Ito, Tori Kurasaki, et al.Virchows Archiv : an International Journal of Pathology|July 19, 2005
Expression of BAFF-R (BR 3) in normal and neoplastic lymphoid tissues characterized with a newly developed monoclonal antibodyNaoya Nakamura, Hidenori Hase, Daisuke Sakurai, et al.Medical Oncology (Northwood, London, England)|May 20, 2008
Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphomaAnri Saitoh, Miwako Narita, Norihiro Watanabe, et al.International Journal of Hematology|July 26, 2018
Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe methodHidekazu Itamura, Masaru Ide, Akemi Sato, et al.International Journal of Hematology|November 28, 2025
A phase 2 study of ibrutinib with venetoclax in Japanese patients with untreated CLL and SLLJun Takizawa, Isao Yoshida, Yoshiaki Ogawa, et al.Internal Medicine (Tokyo, Japan)|September 17, 2014
Manifestations of fulminant CD8 T-cell post-transplant lymphoproliferative disorder following the administration of rituximab for lymphadenopathy with a high level of Epstein-Barr Virus (EBV) replication after allogeneic hematopoietic stem cell transplantationTomoyuki Tanaka, Jun Takizawa, Shukuko Miyakoshi, et al.Hematological Oncology|October 21, 2017
Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapyKeisuke Kawamoto, Hiroaki Miyoshi, Takaharu Suzuki, et al.[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|January 16, 2018
[Myelodysplastic syndrome with refractory hemorrhage due to reduced platelet aggregation activity]Tomoyuki Tanaka, Takashi Kozakai, Toshiki Kitajima, et al.International Journal of Hematology|December 28, 2025
Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in JapanHirotaka Matsui, Jun Takizawa, Kensuke Kojima, et al.Biochemical and Biophysical Research Communications|June 26, 2022
YAP1/TAZ activity maintains vascular integrity and organismal survivalShun Uemura, Masayuki Yamashita, Kazumasa Aoyama, et al.Pageof 8